Internalizing ErbB2 antibodies
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Marie Alix Poul
Life of this patent
Estimating the term…
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Claims19
A method of specifically delivering an effector molecule to a cell bearing a c-erbB2 receptor, said method comprising:
- providing a chimeric molecule comprising said effector molecule attached to an internalizing antibody that specifically binds to the c-erbB2 receptor, wherein said antibody specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA7843) or C1 (SEQ ID NO:
- 2);
- and,
- contacting said cell bearing a c-erbB2 receptor with said chimeric molecule, whereby said chimeric molecule specifically binds to said cell, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.
A method of specifically delivering an effector molecule to a cell bearing a c-erbB2 receptor, said method comprising:
- providing a chimeric molecule comprising said effector molecule attached to an internalizing antibody that specifically binds to the c-erbB2 receptor, wherein said antibody specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA7843) or C1 (SEQ ID NO:
- 2);
- and,
- contacting said cell bearing a c-erbB2 receptor with said chimeric molecule, whereby said chimeric molecule specifically binds to said cell, wherein said cell is a cancer cell.
A method of specifically delivering an effector molecule to a cell bearing a c-erbB2 receptor, said method comprising:
- providing a chimeric molecule comprising said effector molecule attached to an internalizing antibody that specifically binds to the c-erbB2 receptor, wherein said antibody specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA7843) or C1 (SEQ ID NO:
- 2);
- and
- contacting said cell bearing a c-erbB2 receptor with said chimeric molecule, whereby said chimeric molecule specifically binds to said cell, wherein said chimeric molecule is a fusion protein.
A method of specifically delivering an effector molecule to a cell bearing a c-erbB2 receptor, said method comprising:
- providing a chimeric molecule comprising said effector molecule attached to an internalizing antibody that specifically binds to said c-erbB2 receptor, wherein said internalizing antibody specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA7843) or C1 (SEQ ID NO:
- 2), and wherein said internalizing antibody has a binding affinity for c-erbB2, on cells, of less than 10−6M;
- and,
- contacting said cell bearing said c-erbB2 receptor with said chimeric molecule, whereby said chimeric molecule specifically binds to said cell.
Dependencies are inferred from the claim text.